|
Click
on the area of interest on the map
|
CANADA
Montreal
 Caprion
is a drug discovery company applying proteomics to discover and
develop innovative products for the diagnosis and treatment of disease.
With its integrated technology platform and unique expertise in
cell fractionation, Caprion uncovers the proteomic changes involved
in disease, and delivers novel targets to develop effective new
treatments for cancer and other diseases. Caprion and its pharmaceutical
industry partners then use these targets as the basis for new diagnostics
or drugs, the earliest being diagnostic products for Mad Cow Disease
and variant Creutzfeldt-Jacob's Disease (vCJD). Caprion's goal is
to become a fully-integrated drug discovery company offering a broad
suite of resources in custom discovery research programs.
|
 ProMetic
develops synthetic organic entities known as Mimetic Ligands™,
which are designed to effect very specific interactions with proteins.
Of particular interest is ProMetic's involvement in genomics, proteomics
and monoclonal antibodies where chemical ligands are used not only
to purify promising therapeutics, but can become lead compounds for
drug discovery programs as protein/peptide mimetic. To date, ProMetic
has developed and manufactured large scale Mimetic Ligands™ for
a wide range of therapeutics derived from plasma, recombinant or transgenic
sources. |
|
Toronto
 The
Company's proprietary, integrated drug discovery process is designed
for rapid advancement of small molecule programs from gene to clinic.
Affinium is actively engaged on its own internal small molecule
programs. The Company's processes enable high throughput target
production, determination of target function/structure, and determination
of target structure with bound chemicals to enhance and accelerate
chemistry for new medicines. The Company's Pharmaceutical Proteomics™
processes are enhanced by strategic partnerships with Bruker Daltronics
and Bruker BioSpin and Bruker AXS for mass spectrometry, NMR, and
X-ray crystallography technologies, and Aurora BioSciences, now
a wholly owned company from Vertex Pharmaceuticals, to advance AffiniumÕs
internal programs. The Company is continuing to forward integrate
its capabilities to becoming a leading structure based drug design
and development company.
|
 MDS
Proteomics' is a proteomics-based drug discovery company and is forming
a small number of broad collaborations with leading biopharmaceutical
companies. The company's goal is to help its partners increase their
productivity through rapidly identifying, triaging and selecting more
functionally annotated drug targets in disease. MDS Proteomics applies
its proprietary proteomic approaches in novel ways, in order to increase
the probability of clinical success of targets and reduce the time
associated with its partner's drug discovery and development processes.
This will lead directly to the design and development of more effective
and safer medicines, faster. MDS Proteomics has developed a fully
automated, large-scale proteomics' platform that seamlessly fuses
ultra-sensitive mass spectrometry systems, pathway biology, high-performance
supercomputing, computational design and drug screening technology.
MDS Proteomics employs over 200 people in its next-generation proteomics'
facilities in Europe and North America. The company focuses on target
discovery and development for both antibody and small molecule therapeutics
and presently has a number of candidate targets in pre-clinical discovery.
|
|
 SYNX
Pharma Inc. is a fully integrated proteomics research and development
company dedicated to prevention and management of diabetes, cardiovascular
and central nervous system diseases. The company leverages its Proteomics
Discovery Platform™ to deliver disease-associated biomarkers
for the development of new drugs and highly specialized antibody-based
diagnostics by analyzing human biological material. SYNX brings
value-added solutions to its partners by helping them expand the
market for current therapies, while significantly shortening the
drug discovery and testing process, resulting in products being
brought quickly to market, thereby extending their functional commercial
life. Physicians also benefit from SYNX's expertise, by being able
to diagnose disease in its earliest stages, follow its progression
and suggest the most effective course of treatment to improve patient
outcomes.
|
|
Proteomics
and Bioinformatics Group (Samuel Lunenfeld Research Institute)
E.
coli Structural Proteomics Group (U of Toronto)
Arrowsmith
Lab (U of Toronto)
Biomolecular
NMR Group (Ontario Cancer Institute; U of Toronto)
Edwards
Lab (U of Toronto)
Ontario
Structural Proteomics Group
Program
in Proteomics and Bioinformatics (U of Toronto)
SLRI-
MASS Spectometry Facility (Samuel Lunenfeld Research Institute)
|
|
Quebec
A Canadian
Biopharmaceutical company with a cutting-edge technology in Functional
Proteomics. Aurelium is identifying and developing novel Lead targets
and drugs for the treatment of cancer and infectious diseases. Aurelium
has several patented technologies that are used for identifying
Lead targets for drug development and developing novel anticancer
and antimicrobial drugs. Aurelium's technology is based on a breakthrough
in the understanding of protein-protein interactions. This technology
is expected to revolutionize the process of identifying targets
for drug development in the pharmaceutical industry.
|
|
Winnipeg
 ProteoMetrics,
LLC is a bioinformatics company that develops innovative software
to rapidly identify and characterize proteins. The company developed
out of an academic effort to more effectively utilize proteomic
research and has now expanded into the commercial sector. Currently,
a major focus of our activity is the development of an advanced
intranet framework to support large-scale, high-throughput proteomics
projects.
|
|
|
|
